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Background. Varicella zoster virus (VZV) may cause encephalitis, both with and without rash. Here we investigate whether 
viruses recovered from the central nervous system (CNS; encephalitis or meningitis) differ genetically from those recovered from 
non-CNS samples.
Methods. Enrichment-based deep sequencing of 45 VZV genomes from cerebral spinal fluid (CSF), plasma, bronchoalveolar 
lavage (BAL), and vesicles was carried out with samples collected from 34 patients with and without VZV infection of the CNS.
Results. Viral sequences from multiple sites in the same patient were identical at the consensus level. Virus from vesicle fluid 
and CSF in cases of meningitis showed low-level diversity. By contrast, plasma, BAL, and encephalitis had higher numbers of variant 
alleles. Two CSF-encephalitis samples had high genetic diversity, with variant frequency patterns typical of mixed infections with 
different clades.
Conclusions. Low viral genetic diversity in vesicle fluid is compatible with previous observations that VZV skin lesions arise 
from single or low numbers of virions. A similar result was observed in VZV from cases of VZV meningitis, a generally self-limiting 
infection. CSF from cases of encephalitis had higher diversity with evidence for mixed clade infections in 2 cases. We hypothesize 
that reactivation from multiple neurons may contribute to the pathogenesis of VZV encephalitis.
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Primary infection with varicella zoster virus (VZV), an alphaher-
pesvirus, causes chickenpox (varicella). Following latency in the 
neurons of peripheral sensory ganglia, VZV reactivates in 30% to 
cause herpes zoster (shingles). Around 50% of herpes zoster cases 
occur in subjects with reduced cell-mediated immunity [1–3]. In 
common with other alphaherpesviruses, VZV is able to infect the 
central nervous system (CNS) to cause encephalitis, either as a com-
plication of varicella or herpes zoster, but also in the absence of rash.
Studies of equid herpesvirus1 (an alphaherpesvirus of 
horses) have reported that a naturally occurring point mutation 
in the viral DNA polymerase significantly increases the risk of 
encephalitis [4]. Here we examine whether VZV that infects the 
CNS shares certain sequence motifs either uniquely or more 
frequently than non-CNS VZV infections. VZV exclusively 
infects humans and there are no animal models that recapitulate 
the biology or clinical presentation of VZV encephalitis.
METHODS
Sample Collection and Ethics
The samples (Table 1) used in this study were obtained either 
as part of routine care or through prospective research/clinical 
studies. Four cerebrospinal fluid (CSF) samples were obtained 
via the UK Meningitis Study, where ethical approval was given by 
the North Wales Multicentre Research Ethics Committee (refer-
ence 11/WA/0218). All samples were subsequently transferred 
to Great Ormond Street Hospital for Children (GOSH) for pro-
cessing. Purified DNA was stored at −80°C prior to sequencing. 
The use of all samples for research was subsequently approved 
through the University College London Partners Infection 
DNA Bank by the National Research Ethics Service Committee, 
London, Fulham (Research Ethics Committee reference 
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12/LO/1089). All samples tested negative for the VZV live-at-
tenuated vaccine.
Library Preparation, Deep Sequencing, and Assembly
Sequence libraries were constructed from 200  ng of starting 
DNA, derived from original GOSH DNA extracts, supplemented 
with human DNA (Promega, G1471) where necessary. DNA 
was sheared on a Covaris E220 (peak incident power, 175; 
duty factor, 5; cycle per burst, 200; treatment time  =  150  s). 
Multiplexed libraries were run on Illumina MiSeq or NextSeq 
sequencers. Paired-end sequence data were demultiplexed and 
sequence reads trimmed to remove low quality 3′ bases and 
Table 1. Details of Patient Samples Sequenced in This Study
Identity Age
Source 
Country
Sample 
Type Immune Status Note Diversity
Number 
of Variant 
Alleles
VES1 55 (Patient A) UK Vesicle Immunocompromised Varicella 4.20E-05 2
BAL1 BAL 1.58E-04 33
PLAS1 Plasma 4.90E-05 5
VES2 67 (Patient B) UK Vesicle Immunocompromised Zoster (disseminated) 3.97E-05 8
SPU Sputum 3.28E-05 6
PLAS2 Plasma 8.02E-04 103
CSF3 76 (Patient C) UK CSF Immunocompetent Encephalitis with Zoster 9.75E-05 23
VES27 Vesicle 4.39E-05 1
VES18 2 (Patient D) UK Vesicle Immunocompetent Varicella 7.75E-08 9
VES19 Vesicle 1.60E-05 17
VES20 Vesicle 4.83E-06 2
VES21 Vesicle 3.34E-05 2
VES22 Vesicle 2.58E-05 0
VES4 8 (Patient E) UK Vesicle Immunocompetent Varicella 3.70E-05 2
VES26 3.37E-05 0
VES6 3 (Patient F) UK Vesicle Immunocompetent Varicella 5.81E-06 25
VES25 5.14E-05 0
PLAS3 8 UK Plasma Immunocompromised Zoster 2.83E-06 16
BAL2 10 UK BAL Immunocompetent Zoster 4.45E-05 25
CSF1 42 UK CSF Immunocompetent Encephalitis 4.58E-04 133
CSF2 32 UK CSF Immunocompetent Encephalitis 2.38E-04 169
CSF4 81 Sweden CSF Immunocompetent Encephalitis 3.42E-05 21
CSF5 70 Sweden CSF Immunocompetent Encephalitis 6.24E-05 31
CSF6 58 Sweden CSF Immunocompetent Encephalitis 8.35E-05 14
CSF7 54 Singapore CSF Immunocompetent Encephalitis + Zoster 3.30E-05 85
CSF8 (UKM1018a) 28 UK CSF Immunocompetent Meningitis 2.81E-05 11
CSF9 (UKM1211a) 29 UK CSF Immunocompromised Meningitis 6.03E-05 5
CSF10 (UKM0338a) 22 UK CSF Immunocompetent Meningitis 2.23E-06 6
CSF11 (UKM0624a) 69 UK CSF Immunocompetent Meningitis 3.41E-05 2
CSF12 74 UK CSF Immunocompetent Encephalitis 1.00E-04 0
VES3 61 UK Vesicle Immunocompromised Zoster 5.64E-05 8
VES5 8 UK Vesicle Immunocompromised Varicella 3.17E-05 1
VES7 62 Sweden Vesicle Immunocompetent Zoster 1.34E-05 2
VES8 74 Sweden Vesicle Immunocompetent Zoster 2.21E-05 3
VES9 69 Sweden Vesicle Immunocompetent Zoster 1.52E-05 42
VES10 89 Sweden Vesicle Immunocompetent Zoster 3.31E-05 6
VES11 76 Sweden Vesicle Immunocompromised Zoster 2.43E-05 4
VES12 90 Sweden Vesicle Immunocompetent Zoster 2.27E-05 2
VES13 80 Sweden Vesicle Immunocompetent Zoster 4.79E-05 3
VES14 79 Sweden Vesicle Immunocompetent Zoster 1.53E-05 3
VES15 83 Sweden Vesicle Immunocompetent Zoster 4.70E-05 4
VES16 44 Singapore Vesicle Immunocompetent Varicella 1.96E-05 3
VES17 4 Germany Vesicle Immunocompetent Varicella 4.14E-05 6
VES23 10 Italy Vesicle Immunocompetent Varicella 2.00E-05 0
VES24 66 Sweden Vesicle Immunocompetent Zoster 1.22E-05 0
Abbreviations: BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; PLAS, plasma; SPU, sputum; VES, vesicle.
aUK Meningitis Study.
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adapter sequences using TrimGalore (http://www.bioinformat-
ics.babraham.ac.uk/projects/trim_galore/). Read pairs were 
aligned against the VZV reference strain Dumas (NC_001348) 
using BBMap (http://sourceforge.net/projects/bbmap/) while 
duplicate read pairs were removed using MarkDuplicates 
(http://broadinstitute.github.io/picard) and local realignment 
performed using IndelRealigner [5]. SAM, BAM, and mpileup 
files were parsed using SAMTools [6], VarScan2 [7], and custom 
PERL scripts to produce both a consensus sequence for each 
sample and frequency profile for sites with 2 or more alleles 
present. For further analysis variant alleles were filtered using 
bam-readcount (https://github.com/genome/bam-readcount) 
and the fpfilter function in VarScan2 [7]. These combine to flag 
and remove artefactual variant alleles generated by sequencing/
mapping errors.
Multiple Sequence Alignment and Network Phylogeny
Using Mafft v7 [8], consensus sequences were aligned to ref-
erence VZV sequences derived from the 6 major clades [9] 
(Supplementary Table 1) and visualized using SplitsTree4 [10]. 
The 5 small repeat regions, R1-R5, and the terminal repeat region 
were masked from the alignment prior to tree construction.
Nucleotide Diversity Estimates
Base counts at each position of each sample’s read alignment 
were extracted to calculate within-host nucleotide diversity 
(π), defined as the average number of nucleotide differences 
between reads at a site [11] . Strand-bias and random error rates 
were estimated and corrected for using maximum likelihood 
methods.
Statistical Analyses
The Student t test was used to compare numbers of variant 
alleles present in samples grouped according to pathology, 
sample type, and immune status. The Kolmogorov-Smirnov 
(nonparametric) test was used to discern whether variant allele 
frequency distributions differed between vesicle and nonvesicle 
populations.
RESULTS
Description of Samples and Sequencing
Forty-five diagnostic clinical samples, obtained from a total of 
34 patients with VZV-related conditions, were sequenced fol-
lowing enrichment for VZV DNA [12, 13]. For most patients, 
a single sample was available from skin vesicles (VES), CSF, 
plasma (PLAS), sputum (SPU), or bronchoalveolar lavage 
(BAL) (Table 1). Six patients had samples from multiple com-
partments (Table  1), enabling intrahost comparisons of VZV 
populations. Reference-guided alignments of paired-end reads 
to the VZV reference strain Dumas (NC_001348) were gener-
ated for each sample. The percentage of VZV mapping reads 
(on-target reads), which we have previously shown can act as 
a proxy for pathogen load [14], ranged from 3.68% to 91.8% 
(median 79.7%). Genome coverage ranged from 98.46%–100% 
at 1 × coverage to 0.34%–100% at 20 ×, with 35/45 samples hav-
ing over 75% coverage at 100 ×, reflecting the highly variable 
numbers of VZV-mapping reads in each dataset (Supplementary 
Table 2).
VZV Consensus Sequences Do Not Differ Between Body Compartments
A consensus sequence was generated for each sample and 
aligned with 12 VZV genomes, representative of 6 differ-
ent clades obtained from Genbank (Supplementary Table  1). 
A phylogenetic network [10] showed all but 2 sequences (CSF1 
and CSF2) to cluster within established geographic clades 
(Figure 1). As described previously [9], the most parsimonious 
explanation at the time for the positioning of CSF1 and CSF2 
was that both represent interclade recombinant strains. In 6 
patients where multiple samples were obtained, VZV consen-
sus sequences obtained from distinct compartments were iden-
tical. No VZV consensus genome sequences clustered by body 
compartment, and no single-nucleotide polymorphisms or 
sequence motifs were uniquely shared by VZV genomes present 
in the CSF (Figure 1).
VZV Population Heterogeneity Varies by Body Compartment
We next generated estimates of within (intra-) sample nucle-
otide (population) diversity (Figure  2). Our method counts 
the numbers of reads supporting each allele at every site in the 
genome, calculates the nucleotide diversity at each position, and 
assigns a probability of the observed read distributions being 
true. The result computes diversity as a function of allele num-
ber and frequency, with larger numbers of low-frequency alleles 
generally having low diversity values. Nucleotide diversity (π) 
was lowest in vesicle fluid (mean π = 2.80E-05) compared to all 
other sampled compartments, including sputum (single sample, 
π = 3.28E-05), BAL (mean π = 1.01E-04), CSF (mean π = 1.03E-
04), and plasma (median π = 2.85E-04). Nucleotide diversities 
of 2 samples, CSF1 and PLAS2, exceeded 2 standard deviations 
from the mean and were considered outliers (Figure 2). A sec-
ond CSF sample, CSF2, while not statistically an outlier, was 
more diverse than the remaining samples (Figure 2).
For subsequent analyses, variant alleles were filtered to flag 
and remove artefactual variant alleles generated by sequenc-
ing/mapping errors. Plots of the frequencies of filtered vari-
ant alleles and their positions along the genome are shown 
for vesicle (Supplementary Figure  1) and nonvesicle samples 
(Supplementary Figure 2). A second, vertical plot is included for 
each sample (shown to the right of the variant allele distribution 
plots) and shows the distribution of allele frequencies binned 
at 1% intervals (0%–100%) present in each sample irrespective 
of their genomic location (Supplementary Figures  1 and 2). 
Together, these plots were used to look for unusual patterns of 
variant allele frequency distributions. The VZV populations 
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in each sample contained between 0 and 169 variant alleles 
(median = 6; Figure 3). Vesicle fluid sequences had the lowest 
numbers of variant alleles, that is between 0 and 42 (Figure 3). 
For patients A, B, and C, from whom multiple samples from 
different body compartments had been obtained, the vesicular 
fluid variants tended to be fewer than those present in other 
samples (Table  1 and Figure  3). Although individual vesicles 
sampled from the same individual (ie, patients D, E, and F), var-
ied in their numbers of variants (ie, from 0 to17 for patient D, 
0 to 22 for patient F, 0 and 4 for patient E; Table 1), in each case 
the population of variant alleles was distinct (Supplementary 
Figures 2 and 3). The majority of variant alleles in vesicles were 
present at low frequencies (95% < 20% frequency), regardless 
of total numbers, resulting in a distribution shifted towards 
low frequencies. For example although the numbers of variant 
alleles in VES6 and VES9 were the highest of vesicular fluid 
samples (25 and 42, respectively) the frequency with which they 
occurred was still very low (Supplementary Figure  2, vertical 
graphs). Similarly, for patients D, E, and F, although different 
vesicles had different numbers of alleles, the variant frequency 
profile was also low (Figure  3 and Supplementary Figure  2). 
While the vesicular and meningitis samples (CSF8, CSF9, 
CSF11, CSF12) largely had fewer than 10 variant alleles (24/27 
samples and 3/4 samples, respectively) (Table 1 and Figure 3), 
14/16 nonvesicular samples had more than 10 variant alleles 
(median = 19; Figure 3) with more evidence of high-frequency 
variants (Supplementary Figure  1). The difference between 
allele numbers in vesicular and nonvesicular samples was sig-
nificant (Student t test, P < .001) as it was between vesicular and 
encephalitis samples (Student t test P < .05).
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Figure 1. Network phylogeny identifies 2 putative interclade recombinant varicella zoster virus (VZV) genomes. Phylogenetic network of 55 VZV genomes, including 45 from 
this study and 10 representative the 6 major geographic clades (numbered 1–6). CSF1 and CSF2 represent putative interclade recombinants. Sample types are color coded. 
Abbreviations: BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; PLAS, plasma; SPU, sputum; VES, vesicle.
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Nonvesicular samples also showed a different distribution 
of variant allele frequencies (Kolmogorov-Smirnov, P  <  .001) 
compared to vesicular fluid (Supplementary Figure  4). The 3 
most variable samples (PLAS2, CSF1, and CSF2; Figure 2), had 
distinct patterns of variant allele frequencies suggestive of the 
presence of minor viral populations (Figure 5). Variant num-
bers sampled from multiple sites mostly reflected sample ori-
gin, with vesicular samples having lower numbers than samples 
taken from CSF, BAL, or plasma in the same patients (Figure 3 
and 4). There was no difference in the number of variant alleles 
in vesicle samples by disease (Student t test, P =  .50, varicella 
versus zoster) or immune status (Student t test, P = .79, immu-
nocompetent versus immunocompromised). All bar 1 of the 
CSFs were from immunocompetent patients either with CNS 
disease alone or with concomitant herpes zoster and there were 
too few of the other sample types for statistical analysis.
High Nucleotide Diversity Values are Indicative of Superinfections and/or 
Prolonged Infections
To investigate whether the increased nucleotide diversities of 
samples CSF1, CSF2, and PLAS2 were due to mixed infections, 
we substituted variant alleles within distinct frequency ranges 
into the consensus sequences for the same samples and generated 
additional network phylogenies. For CSF1, the putative minority 
genome was present at a frequency of 22%–46%. Substituting the 
variant alleles occurring at this frequency into the clade 3 consen-
sus sequence resulted in a sequence that mapped most closely to 
clade 1 viruses and reexamining the CSF1 sequence data shows it 
not to be an interclade recombinant but rather a mixture of clades 
1 (minority) and 3 (majority) viruses (Figure 5A). For CSF2, a 
normally distributed subpopulation was observed in a frequency 
range 6%–12%. The minority sequence was found to cluster most 
closely with clade 3 viruses (Figure 5B). The low-level clade 3 vari-
ant was distinct from the dominant consensus sequence, a recom-
binant clade 1/3 virus (Figure 5B) [9]. PLAS2, where the putative 
subpopulation, albeit less distinct than for CSF1 and CSF2, was 
distributed between frequencies of 6% and 22%, and did not yield 
a different clade type. The distribution of variant alleles across the 
genome also differed for PLAS2 with several groups of variant 
alleles appearing in localized clusters, not observed for other 
samples, including CSF1 and CSF2 (Figure 5C). Further analy-
sis of PLAS2 showed over 39% of variant alleles clustered in 3 
glycoproteins, ORF31 (glycoprotein B), ORF37 (glycoprotein 
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H), and ORF68 (glycoprotein E), as well as the ORF20 (capsid) 
and ORF22 (large tegument) genes. Inspection of sequence read 
quality scores and alignments strongly suggested these variant 
alleles did not arise through artefacts, although insufficient mate-
rial remained for polymerase chain reaction or resequencing. As 
a control, we repeated the analyses for all other samples with 10 
or more variant alleles (Table 1 and Supplementary Figures 1 and 
2) and determined that these infections had neither mixed clade 
infections nor mutations clustering in the above open reading 
frames.
DISCUSSION
These results are compatible with previous conclusions that 
individual skin vesicles are typically founded by 1 to 3 virions 
[13], a significant population bottleneck that limits subsequent 
viral population diversity within vesicles. Our previous studies 
made use of the vOka vaccine, which contains a mixture of re-
lated strains each of which carries a different subset of the ap-
proximately 140 known vaccine mutations [15]. Each vOka 
virion is effectively “barcoded,” enabling tracking of their fate 
following vaccine inoculation [6, 15, 16]. In this study, 24 out 
of 27 sampled vesicle populations contained fewer than 10 var-
iant alleles. High and low copy number vesicles occurred within 
the same patient (eg, D, VES19 and VES25 and F, VES6 and 
VES25) and differences in vesicular copy number were not 
explained by clinical characteristics (age, immunosuppression, 
disease) (Table 1). We therefore suggest that the 3 vesicular flu-
ids (VES 6, VES9, and VES19) with higher diversity (Figure 3) 
are explained by these samples containing genetic material in-
advertently sampled from multiple vesicles; similar levels of di-
versity were obtained when pooling deep sequence from all 5 
patient D vesicles (Supplemental Figure 3).
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By contrast, although numbers were small, we observed sig-
nificantly higher diversity in CSF from cases of encephalitis, 
with 7 out of 8 CSF samples from these patients having greater 
than the median numbers of variants, as compared with vesicu-
lar fluid and CSF samples from patients with meningitis (CSFs 
8–11) (P  <  .05). Viral diversity was not related to viral load, 
which we have previously shown can be inferred in relatively 
acellular fluids such as CSF from the percentage of on-target 
reads [14]. Instead the highest diversity in CSF1 and CSF2 was 
due to mixed infection with 2 or more different VZV clades. 
CSFs 1 and 2 came from immunocompetent patients present-
ing with acute encephalitis and no skin rash. Both patients had 
past histories of chickenpox with no history of recent exposure. 
We conclude that their encephalitides are likely to have arisen 
from viral reactivation, most probably, given the mixed geno-
types present, originating from multiple neurons or ganglia. We 
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at 1% frequencies and are displayed in a horizontal bar chart (right side). A normally distributed subpopulation of alleles (dotted red box) is suggestive of a mixed infection. 
Subpopulations are shown in the network phylogenies (right) (major sequence, blue circle; minor sequence, red circle). Abbreviations: CSF, cerebrospinal fluid; PLAS, plasma.
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have previously shown latent infection and reactivation in the 
same individual, at different times, of VZV belonging to differ-
ent clades [17]. How often infection and latency with multiple 
viruses occurs is not known, especially as distinguishing viruses 
from the same clade is difficult. Nonetheless, in an observational 
study of African and Asian patients who developed zoster after 
migrating as adults to the United Kingdom, having had varicella 
in their country of origin, 30% reactivated a UK genotype rather 
than the clades 4 and 5 prevalent in their countries of origin [18]. 
Reinfection and latency followed by reactivation of European 
clade wild-type viruses is also well described for subjects who 
have seroconverted to the Japanese vOka vaccine strain [19]. 
We and others have previously shown that the natural history 
of VZV is characterized by extensive genetic recombination 
between VZV strains from different geographic clades [11, 20]. 
Recombination requires 2 distinct virions to be present in the 
same cell. Our finding of 2 patients with evidence for multiple 
strains replicating simultaneously in CSF highlights the nervous 
system as a potential site for recombination to occur.
Other encephalitis samples such as CSF7, with high vari-
ant numbers at low frequencies, could represent reactivation 
of the same clade-virus from multiple sites, giving a similar 
allelic frequency profile as the pooled patient D vesicle alleles 
(Supplementary Figure 3). In contrast, virus from cases of men-
ingitis shows similar diversity to that of vesicular fluid, pointing 
to the possibility that self-limiting VZV meningitis is caused 
by reactivation and replication of VZV from very few neu-
rons. Alternatively, the diversity observed in encephalitis cases 
could be due to accumulating mutations, perhaps driven by 
the immune system. In this scenario, more-severe cases where 
virus spreads to brain parenchyma to cause encephalitis could 
be due to poorer immune control with more evidence of escape 
mutations. This latter hypothesis would not, however, account 
for the mixed clades observed in CSFs 1 and 2, and is less easy 
to explain in the context of young immunocompetent patients 
such as those described here.
Two other samples with higher viral diversity, PLAS2 and 
BAL1, both came from patients with profound immunosup-
pression. We have previously shown the presence of a mixed 
vOka founder population in endotracheal aspirates from a 
case of vOka pneumonitis in an immunocompromised child, 
presumably from the multiple foci of infection in the lungs. 
Vesicular fluid from the same child was, as expected, derived 
from a single virion [21]. Extrapolating to this study, the larger 
numbers of variant alleles present in bronchoalveolar lavage 
and plasma samples could have arisen from multiple virions 
spilling over from the tissues in which they were replicating. 
Prolonged viral replication in the presence of poor immune 
control is likely to exacerbate diversity and may account for 
the extremely high numbers of variants seen in PLAS2 from 
patient B, a renal transplant recipient with an undiagnosed, 
disseminated VZV infection for at least 10  days prior to the 
sample being collected [22]. The high concentration of these 
variants in surface-expressed proteins may reflect viral muta-
genesis in response to immune pressures. Patient B developed 
respiratory failure as a late manifestation of their illness [22] 
and a sputum sample taken at the same time as PLAS2 showed 
low diversity with few variant alleles. By contrast Patient A, 
also a renal transplant recipient, had very few variant alleles 
in plasma (PLAS1) although more in the BAL (BAL1). Patient 
A  presented with varicella and pneumonitis, and the plasma 
sample was taken at presentation approximately 19  days fol-
lowing contact with patient B, the source of patient A’s infec-
tion (ie, at the onset of illness and possibly before extensive 
replication had occurred). The higher nucleotide diversity of 
VZV populations in the lungs, compared to plasma, could be 
explained by virus having spread more widely and replicated 
for longer in the lungs at this early stage. Plasma samples 
from later in the course of infection were not available but we 
would speculate that they may have shown increasing diversity. 
Patient A did not show the variant clustering seen in patient 
B. Because patient A, unlike patient B, was VZV-naive before 
infection [22], their lack of viral heterogeneity may reflect the 
absence of immune-driven mutagenesis.
In summary, using genetic studies we have shown that, like 
the VZV vOka vaccine strain, vesicles arising during VZV 
wild-type infections are likely to be founded by few virions, a 
major bottleneck event that results in restricted genome diver-
sity within vesicles as the founder VZV population expands 
[13]. By contrast, we found evidence that cases of encephalitis 
may be more diverse. The evidence of mixed clade infections 
and high viral diversity are most parsimoniously explained by 
reactivation of multiple founder viruses causing encephalitis 
with reactivation of a few causing the less diverse meningitis. 
Alternatively, we cannot exclude the possibility that some of 
the increased diversity seen in encephalitis (although not the 
mixed clades) is due to accumulating escape mutations, possi-
bly resulting from incomplete immune control. Fifty percent of 
VZV encephalitis cases occur in association with immunosup-
pressive conditions in which viral reactivation is known to be 
more common. The factors predisposing to widespread VZV 
reactivation in younger immunocompetent patients are more 
difficult to explain. It is possible that in these subjects genetic 
factors are important. This hypothesis has resonances with the 
finding that herpes zoster in younger patients (<40 years) con-
fers a significantly higher lifetime risk of stroke, a finding that 
has been mooted [23] to reflect a genetic predisposition to VZV 
reactivation both symptomatic and asymptomatic. Importantly, 
although sample numbers were low we do not find any evi-
dence that VZV strains recovered from the CNS share poly-
morphisms that distinguish them from VZV strains recovered 
from other (non-CNS) compartments. These findings suggest 
that VZV infection of the CNS is unlikely to be due to single 
viral polymorphisms.
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Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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